ONO 8539

Drug Profile

ONO 8539

Alternative Names: ONO-8539

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Hyogo College of Medicine; Ono Pharmaceutical
  • Class
  • Mechanism of Action Prostaglandin-E EP1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastro-oesophageal reflux; Overactive bladder

Most Recent Events

  • 25 Nov 2014 Phase-I/II clinical trials in Gastro-oesophageal reflux in Japan (PO) (UMIN000015753)
  • 31 Mar 2014 Ono Pharmaceutical completes a phase I trial in Healthy volunteers in United Kingdom (NCT01705275)
  • 16 Jan 2014 Ono Pharmaceutical completes enrolment in its phase I trial in Healthy volunteers in United Kingdom (NCT01705275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top